{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/zh\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen \u6682\u505c\u5916\u663e\u5b50 51 \u8df3\u8dc3\u7814\u7a76"},"content":{"rendered":"<p class=\"wp-block-paragraph\">PepGen \u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u63a8\u8fdb\u4e0b\u4e00\u4ee3\u5be1\u6838\u82f7\u9178\u7597\u6cd5\uff0c\u65e8\u5728\u6539\u53d8\u4e25\u91cd\u795e\u7ecf\u808c\u8089\u548c\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\u7684\u6cbb\u7597\u65b9\u6cd5\uff0c\u4eca\u5929\u8be5\u516c\u53f8\u5ba3\u5e03\u81ea\u613f\u51b3\u5b9a\u6682\u505c\u5bf9\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD) \u60a3\u8005\u8fdb\u884c PGN-EDO51 \u7684 2 \u671f CONNECT2-EDO51 \u7814\u7a76\uff0c\u76f4\u5230\u516c\u53f8\u80fd\u591f\u5ba1\u67e5\u6b63\u5728\u8fdb\u884c\u7684 2 \u671f CONNECT1-EDO51 \u7814\u7a76\u4e2d 10 mg\/kg \u7ec4\u7684\u7ed3\u679c\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CONNECT1 \u7814\u7a76\u7684\u524d\u4e24\u4e2a\u961f\u5217\u5df2\u5168\u90e8\u62db\u52df\u5b8c\u6bd5\uff0c\u9884\u8ba1 10 mg\/kg \u961f\u5217\u7684\u6570\u636e\u5c06\u4e8e 2025 \u5e74\u7b2c\u4e09\u5b63\u5ea6\u83b7\u5f97\u3002\u81ea\u516c\u53f8\u4e0a\u6b21\u4e8e 2025 \u5e74 1 \u6708 23 \u65e5\u8fdb\u884c\u5b89\u5168\u66f4\u65b0\u4ee5\u6765\uff0c\u672a\u53d1\u73b0\u4e0e PGN-EDO51 \u76f8\u5173\u7684\u65b0\u7684\u5b89\u5168\u95ee\u9898\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}